not losing weight on oral semaglutide FDA Approves for Loss The FDA-approved GLP-1 pill for

so you can finally feel like you again

The incretin effect is defined as the higher stimulation of insulin secretion obtained when glucose is administered orally than intravenously, under similar plasma glucose levels

Regulators (like the FDA in the U.S.) might be pushed to update labeling, add warnings, or require additional studies to better understand long-term effects

Triple agonist retatrutide yielded 28.7% weight loss at 68 weeks, besting Zepbounds Phase III data, while also showing benefit in knee osteoarthritis pain.

| 66 comments on LinkedIn

Mazdutide and Retatrutide represents two of the most fascinating new peptides in modern obesity pharmacotherapy